NYSE-listed pharma major Abbott Labs has inked a deal with Piramal Healthcare to acquire Piramal’s Healthcare Solutions business. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal’s Healthcare Solutions Business. May 21, am. N) will pay $ billion to acquire the branded generics business of Piramal’s healthcare solutions accounted for about 55 percent of its.

Author: Jukus Tajin
Country: Anguilla
Language: English (Spanish)
Genre: Life
Published (Last): 13 March 2014
Pages: 200
PDF File Size: 3.52 Mb
ePub File Size: 17.55 Mb
ISBN: 433-4-78647-609-2
Downloads: 88444
Price: Free* [*Free Regsitration Required]
Uploader: Shakakazahn

Piramal started the pharma business in and has expanded it through organic and inorganic growth.

Mumbai-based Piramal said it would consider paying a special dividend and would use deal proceeds to invest in its remaining businesses and pay down debt. Abbott has been operating in India for of its years, and has popular pharmaceutical brands including the antacid Digene and painkiller Brufen. Obviously, whoever wants to strengthen Indian presence through buyouts, will have to shell out much more due to the higher demand for Indian assets.

My watch list My saved searches My saved topics My newsletter Register free of charge.

Abbott buys Piramal’s Healthcare Solutions – PMLiVE

The Thomson Reuters Trust Principles. Leave Your Comment s. Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates ADCsa growing niche in the development of biopharmace Country Garden, one of the largest and most successful vertically integrated real estate[…]. By comparison, Cipla trades at about 4.

Read what you need to know about our industry portal bionity. Piramal Enterprises enters into an agreement to acquire Ash Stevens Inc. I have forgotten my password.


A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma?

All the cash from the deal will go into Piramal Healthcare and will be invested in existing business segments such as consumer healthcare or the OTC unit, the critical care segment and nealthcare research, chairman Piramal said.

DE please activate JavaScript. In the past few years, they have realized that those pipelines are running dry, and are trying to diversify. Abbott Piramal Healthcare pain neuroscience generics antibiotics. Chaudhuri acknowledges those new realities, but with a patriotic tinge. The Abbott deal is the fourth biggest acquisition of an Indian drug business by a foreign drug maker in the last three years.


In Germany, Abbott has approximately 2, employees working in manufacturing, research and development, logistics, sales and marketing. To use all the functions on Chemie. It is not so much a concern about the downside, but about how we maximize the opportunity. Abbott, which will fund the transaction with cash on the balance sheet, says, the deal will be conducted through its wholly-owned subsidiary.

Unlike other pharmaceutical acquisitions that have been targeted at buying Indian generic capacity to service Western and emerging markets, the Abbott-Piramal deal is primarily focused on the domestic market, according to Mumbai-based business magazine Business India.

Over the past ten years, Abbott has established a leading presence in emerging markets and now more than 20 per cent of the company’s total sales are generated in these growing economies. Piramal justified the sale by saying that future value from the branded generics business would come from business growth outside India.

The combined Abbott and Piramal sales force will be the largest in India, Warmuth said, adding that the price that it paid for the Indian business was just right.


Abbott Products GmbH more. But new Wharton research provides better insight into the benefits of PE buyouts. Abbott and other Big Pharma companies face the twin wbbott of slow growth in the developed markets and maturing product pipelines that are getting harder to replenish with newer, blockbuster drugs, according to Chaudhuri.

The business will continue to be led by its current India-based management team. According to Abbott, this deal further accelerates Abbott’s emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott’s pf with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio.

The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in Many view private equity firms as villainous actors intent on the healthvare goal of profit. It is increasingly a preferred choice for infrastructure and real estate developers as well.

The Indian drug maker, which itself has made 15 acquisitions sinceinsists it will remain in the industry and invest in the remaining business. Acquisitioj, Piramal’s barnds have presence across the emerging markets. Piramal Healthcare, which has shown growth in anti-infective, dermatology, nutritionals and OTC segment, had launched 32 new products and has been ranked no.

BOas global drugmakers look to boost their presence in emerging markets. To use all functions of this page, please activate cookies in your browser.